Efficacy of tadalafil in Egyptian and Turkish men with erectile dysfunction.
A randomised, double-blind, parallel, placebo-controlled, 12-week study was carried out to evaluate the efficacy and safety of 20-mg tadalafil taken 'as needed' in a population of men with erectile dysfunction (ED) from Egypt and Turkey. One hundred and thirty-two patients were randomised in this study. Tadalafil was superior to placebo on all three co-primary efficacy end points. The mean change from baseline for the erectile function domain of the International Index of Erectile Function was 9.3 +/- 0.8 for the tadalafil group and 2.3 +/- 1.6 for the placebo group. Tadalafil-treated patients reported a significantly greater improvement in the mean percentage of successful penetrations (tadalafil: 34.5 +/- 4.1; placebo: -4.6 +/- 8.1) and successful intercourse attempts (tadalafil: 52.2 +/- 3.8; placebo: 16.8 +/- 7.8) than placebo-treated patients as measured by the Sexual Encounter Profile. Tadalafil was generally well tolerated with 82% of adverse events being mild in severity. Tadalafil 20-mg taken 'as needed' significantly improved the erectile function in Egyptian and Turkish men with ED.
Saylan
M
M
Eli Lilly Turkey, Istanbul, Turkey. saylan_mete@lilly.com
Khalaf
I
I
Kadioglu
A
A
Shoair
K Z
KZ
Beheiry
A
A
Wang
W C
WC
Kopernicky
V
V
Esen
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D002243:Carbolines / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004534:Egypt / Q000208:ethnology; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000208:ethnology; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D010410:Penile Erection / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011788:Quality of Life; D000068581:Tadalafil; D016896:Treatment Outcome; D014421:Turkey / Q000208:ethnology
D002243:Carbolines; D010726:Phosphodiesterase Inhibitors; D000068581:Tadalafil